Zacks: Heat Biologics, Inc. (HTBX) Given $2.63 Average Price Target by Brokerages

Shares of Heat Biologics, Inc. (NASDAQ:HTBX) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $2.63 for the company, according to Zacks. Zacks has also given Heat Biologics an industry rank of 171 out of 265 based on the ratings given to related companies.

Shares of Heat Biologics (NASDAQ HTBX) opened at $0.34 on Friday. Heat Biologics has a fifty-two week low of $0.30 and a fifty-two week high of $1.25. The company has a market capitalization of $12.17, a price-to-earnings ratio of -0.08 and a beta of 0.69.

Shares of Heat Biologics are set to reverse split on Monday, January 22nd. The 1-10 reverse split was announced on Friday, January 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 19th.

Heat Biologics (NASDAQ:HTBX) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.30. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. The business had revenue of $0.47 million during the quarter, compared to the consensus estimate of $0.50 million. equities analysts expect that Heat Biologics will post -2.53 EPS for the current fiscal year.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. increased its stake in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 661,388 shares of the biopharmaceutical company’s stock after purchasing an additional 70,290 shares during the quarter. Vanguard Group Inc. owned about 1.86% of Heat Biologics worth $403,000 at the end of the most recent quarter. 7.97% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/20/zacks-heat-biologics-inc-htbx-given-2-63-average-price-target-by-brokerages.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply